References
- Andrews PA, Miller TA, Mushtaq G, Rusch LM, Secrist JP, Richon VM. (2004). Interspecies comparison of the pharmacokinetics and metabolism of SAHA. AACR Meeting Abstracts 2004 45:928–a.
- Benet LZ, Galeazzi RL. (1979). Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68:1071–4.
- Bogaards JJP, Venekampb TJC, Van Bladeren PJ. (1996). The biotransformation of isoprene and the two isoprene monoepoxides by human cytochrome hP450 enzymes, compared to mouse and rat liver microsomes. Chem-Biol Interact 102:169–82.
- Buckpitt AR, Bahnson LS. (1986). Naphthalene metabolism by human lung microsomal enzymes. Toxicology 41:333–41.
- Buckpitt AR, Castagnoli N, Nelson SD, Jones AD, Bahnson LS. (1987). Stereoselectivity of naphthalene epoxidation by mouse, rat, and hamster pulmonary, hepatic, and renal microsomal enzymes. Drug Metab Dispos. 15:491–8.
- Buckpitt AR, Warren DL. (1983). Evidence for the hepatic formation, export and covalent binding of reactive naphthalene metabolites in extrahepatic tissues in vivo. J Pharmocol Exp Ther 225:8–16.
- Cho TM, Rose RL, Hodgson E. (2006). In vitro metabolism of naphthalene by human liver microsomal cytochrome P450 enzymes. Drug Metab Dispos 34:176–83.
- Daly JW, Jerina DM, Witkop B. (1972). Arene oxides and the NIH shift: the metabolism, toxicity and carcinogenicity of aromatic compounds. Experientia 28:1129–49.
- Du L, Musson DG, Wang AQ. (2005). High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum. Rapid Commun Mass Spectrom 19:1779–87.
- Grant S, Easley C, Kirkpatrick P. (2007). Vorinostat. Nat Rev Drug Disc 6:21–2.
- Hiroi T, Imaoka S, Chow T, Funae Y. (1998). Tissue distributions of CYP2D1, 2D2, 2D3 and 2D4 mRNA in rats detected by RT-PCR. Biochim Biophys Acta 1380:305–12.
- Jerina D, Daly J, Witkop B, Zaltzman-Nirenberg P, Udenfreind S. (1968). Role of the arene oxide-oxepin system in the metabolism of aromatic substrates. I. In vitro conversion of benzene oxide to a premercapturic acid and a dihydrodiol. Arch Biochem Biophys 128:176–83.
- Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. (2001). Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194–202.
- Mehvar R. (1991). Relationship of apparent systemic clearance to individual organ clearances: effect of pulmonary clearance and site of drug administration. Pharmaceut Res 8:306–12.
- Miller TA, Witter DJ, Belvedere S. (2003). Histone deacetylase inhibitors. J Med Chem 46:5097–116.
- Minucci S, Pelicci PG. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51.
- Oesch F, Glatt H, Schmassmann H. (1977). The apparent ubiquity of epoxide hydratase in rat organs. Biochem Pharmacol 26:603–7.
- Pakenham G, Lango J, Buonarati M, Morin D, Buckpitt A. (2002). Urinary naphthalene mercapturates as biomarkers of exposure and stereoselectivity of naphthalene epoxidation. Drug Metab Dispos 30:247–53.
- Pescatore G, Kinzel O, Attenni B, Cecchetti O, Fiore F, Fonsi M, Rowley M, Schultz-Fademrecht C, Serafini S, Steinkühler C. (2008). Optimization of a series of potent and selective ketone histone deacetylase inhibitors. Bioorg Med Chem Lett 18:5528–32.
- Pushparajaha DS, Umachandrana M, Nazira T, Planta KE, Planta N, Lewisa DFV, Ioannides C. (2008). Up-regulation of CYP1A/B in rat lung and liver, and human liver precision-cut slices by a series of polycyclic aromatic hydrocarbons; association with the Ah locus and importance of molecular size. Toxicol In Vitro 22:128–45.
- Rosato RR, Grant S. (2004). Histone deacetylase inhibitors in clinical development. Expert Opin Investig Drugs 13:21–38.
- Seidegård J, DePierre JW. (1983). Microsomal epoxide hydrolase. Properties, regulation and function. Biochim Biophys Acta 695:251–70.
- Tsuruda LS, Lamé; MW, Jones AD. (1995). Metabolism of [14C]naphthalene in the B6c3f1 murine isolated perfused liver. Drug Metab Dispos 23:129–36.
- Umehara K, Kudo S, Hirao Y, Morita, S, Ohtani T, Uchida M, Miyamoto G. (2000). In vitro characterization of the oxidative cleavage of the octyl side chain of olanexidine, a novel antimicrobial agent, in dog liver microsomes. Drug Metab Dispos 28:1417–24.
- Zhang Q, Ma P, Iszard M, Cole RB, Wang W, Wang G. (2002). In vitro metabolism of R(_)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo [1,2,3-de]1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate, a cannabinoid receptor agonist. Drug Metab Dispos 30:1077–86.